## **RUBRA MEDICAMENTS LIMITED**

Unaudited financial results for the quarter ended 30th September 2015

PART I								
	Particulars	3 Months Ended 30.09.2015 Unaudited	3 Months Ended 30.06.2015 Unaudited	3 Months Ended 30.09.2014 Unaudited	6 Months Ended 30.09.2015 Unaudited	Corresponding 6 Months Ended 30.09.2014 Unaudited	Year to date figures for the previous year ended 31.03.2015 Audited	
	T	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1	Income From Operations	6.12			6.12	=		
	(a) Income from Operations (b) Other operating Income	0.12	=	- -	6.12	-	-	
	Total Income from Operations (net)	6.12			6.12			
2	Expenditure	0.12			0.12			
S	a. Cost of material consumed	ī	-	-	-	-	-	
	b. Purchases of Stock-in-trade	2.06	-	-	2.06	-	Ξ	
	c. Change in inventories of finished goods. Work-in-Progress and	-	_		-	_	_	
	stock-in-trade	0.45	0.45		0.90		0.42	
	d. Employee benefits expenses e. Depreciation & Amortisation expenses	0.45	0.45	-	0.90	-	0.42	
	f. Other Expenses	3.44	0.92	1.42	4.36	3.93	7.06	
	Total Expenses	5.95	1.37	1.42	7.32	3.93	7.48	
2	Profit from Operations before Other Income, Finance Cost and							
3	Exceptional Items (1-2)	0.17	(1.37)	(1.42)	(1.20)	(3.93)	(7.48)	
4	Other Income	-			-	-	-	
.5	Profit from ordinary activities before Finance Cost and Exceptional	0.17	(1.37)	(1.42)	(1.20)	(3.93)	(7.48)	
	Items (3+4)	****	(-10.7)	(/	(-1)	(0.50)		
6	Finance Costs	-			-	-	-	
7	Profit from ordinary activities after Finance Costs but before Exceptional Items (5-6)	0.17	(1.37)	(1.42)	(1.20)	(3.93)	(7.48)	
8	Exceptional Items (5-0)	_			_	_	_	
	Profit/(Loss) from ordinary activities before Tax (7+8)	0.17	(1.37)	(1.42)	(1.20)	(3.93)	(7.48)	
	Tax Expenses	-	, , , ,		-	-	-	
11	Profit/(Loss) from Ordinary activities After Tax (9-10)	0.17	(1.37)	(1.42)	(1.20)	(3.93)	(7.48)	
	Extraordinary Items (Net of Tax)	1			Ī	-	-	
13	Net Profit / (Loss) for the period (11-12)	0.17	(1.37)	(1.42)	(1.20)	(3.93)	(7.48)	
14	Paid-up Equity Share Capital (Face Value Rs.10/- Each)	546.83	546.83	546.83	546.83	546.83	546.83	
15	Reserve excluding revaluation reserves						(507.75)	
16	Earning per Share (Basic and diluted)*	0.00	(0.00)	(0.00)	(0.00)	(0.01)	(0.01)	
	* Not Annualised							
PART II								
A	PARTICULARS OF SHAREHOLDINGS							
1	Public Shareholding							
	-Number of Shares	5,465,300	5,465,300	5,465,300	5,465,300	5,465,300	5,465,300	
	- Percentage of shareholding	99.95	99.95	99.95	99.95	99.95	99.95	
	Down to 0 Down to Comp Charlet His							
2	Promoter & Promoter Group Shareholding							
	a) Pledged / Encumbered -Number of Shares							
	Percentage of Shares (as a % of the total shareholding of promter and	-	-	-	-	-	-	
	promoter group) Percentage of Shares (as a % of the total share capital of the	=	=	=	=	=	=	
	Company)	-	-	-	-	-	-	
	b) Non Engandoned							
	b) Non-Encumbered							
	-Number of Shares	3000	3000	3000	3000	3000	3000	
	Percentage of Shares (as a % of the total shareholding of promter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00	
	Percentage of Shares (as a % of the total share capital of the Company)	0.05	0.05	0.05	0.05	0.05	0.05	
	I			I		ı	ı	
	Particulars							
В	INVESTOR COMPLAINTS							
	Pending at the beginning of the quarter	0		0	0	0	C	
	Received during the quarter	0		0	0	0		
	Disposed of during the quarter	0		0	0	0		
1	Remaining unresolved at the end of the quarter	0	0		0		0	

- Notes:

  1. The above results were reviewed by the Audit Committee of the Board of Directors in their meeting held today
- $2. \ \ The previous periods figures have been regrouped whereever necessary.$

Remaining unresolved at the end of the quarter

For Rubra Medicaments Limited
Director

Place: Mumbai Date: 14/11/2015

## **RUBRA MEDICAMENTS LIMITED**

## **STATEMENT OF ASSETS AND LIABILITIES**

Α		EQUITY AND LIABILITIES	As on 2015	September 30,	As on March 31, 2015
1	Shareholders Funds				
	(a)	Share Capital		54,683,000	54,683,000
	(b)	Reserves and Surplus		(50,894,635)	(50,774,820)
	(c)	Money received against share warrants		-	
		Sub-total - Shareholders' funds		3,788,365	3,908,180
2	Share	application money pending allotment		-	-
3	Minority interest			-	-
	None	urrent liabilities	1		Ī
4					
	(a) (b)	Long-term borrowings Deferred tax liabilities (net)		746,257	746,257
	(c)	Other long-term liabilities		740,237	740,237
	(d)	Long-term provisions		<u> </u>	_
	(u)	Sub-total - Non-current liabilities		746,257	746,257
		Sub-total Holl current habilities		740,237	740,237
5	Currer	nt liabilities			
	(a)	Short-term borrowings		=	-
	(b)	Trade payables		-	-
	(c)	Other current liabilities		-	-
	(d)	Short-term provisions		-	-
		Sub-total - Current liabilities		-	-
		TOTAL - EQUITY AND LIABILITIES		4,534,622	4,654,437
В		ASSETS			<u> </u>
1	Non-c	urrent assets			
	(a)	Fixed assets		_	_
	(b)	Goodwill on consolidation		_	_
	(c)	Non-current investments		-	-
	(d)	Deferred tax assets (net)		=	-
	(e)	Long-term loans and advances		3,282,070	3,054,070
	(f)	Other non-current assets		168,819	168,819
		Sub-total - Non-current assets		3,450,889	3,222,889
2	Currer	nt Assets			
	(a)	Current investments		-	-
	(b)	Inventories		_	-
	(c)	Trade receivables		177,269	177,269
	(d)	Cash and cash equivalents		906,464	1,254,279
	(e)	Short-term loans and advances		-	-
	(f)	Other current assets		-	-
		Sub-total - Current assets		1,083,733	1,431,548
		TOTAL - ASSETS		4,534,622	4,654,437